Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Pharmacotherapy|November 30, 2011
Strategies for managing heparin therapy in patients with antiphospholipid antibody syndromeTrupti P Mehta, Maureen A Smythe, Joan C MattsonAnnals of Emergency Medicine|March 30, 2005
Delayed-onset heparin-induced thrombocytopeniaMaureen A Smythe, Jennifer L Stephens, Joan C MattsonChest|April 3, 2007
The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospitalMaureen A Smythe, John M Koerber, Joan C MattsonChest|May 21, 2008
The financial impact of heparin-induced thrombocytopeniaMaureen A Smythe, John M Koerber, Maureen Fitzgerald, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 26, 2005
A comparison of lepirudin and argatroban outcomesMaureen A Smythe, Jennifer L Stephens, John M Koerber, et al.The Annals of Pharmacotherapy|December 14, 2004
Effect of lepirudin on the international normalized ratioJennifer L Stephens, John M Koerber, Joan C Mattson, et al.American Journal of Hematology|September 11, 2002
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopeniaMaureen A Smythe, Theodore E Warkentin, Jennifer L Stephens, et al.The Annals of Pharmacotherapy|May 30, 2003
Comparing methods of establishing the aPTT therapeutic range of heparinClaire I Liepman, John M Koerber, Joan C Mattson, et al.Platelets|March 19, 2002
A variant of the Sebastian platelet syndrome with unique neutrophil inclusionsJames G White, Joan C Mattson, William L Nichols, et al.Pharmacotherapy|August 25, 2009
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patientsMaureen A Smythe, John M Koerber, Lisa L Forsyth, et al.Pageof 2